SYNTARA LIMITED — Director's Dealing 2006

Oct 26, 2006

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

		Name of entity PHARMAXIS LTD
A BN	75 082 811 630

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Denis Michael Hanley
Date of last notice	3 October 2006

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Change in direct interest
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to therelevant interest.
Date of change	26 October 2006
No. of securities held prior to change	Ordinary shares held directly: 566,664Ordinary shares held indirectly: 201,333Options over ordinary shares: 1,080,000
Class	Unlisted options
Number acquired	40,000 options
Number disposed	Nil
Value/ConsiderationNote: If consideration is non-eash, provide details andestimated valuation.	Granted under Pharmaxis Employee Option Plan for nilconsideration. Value of $53,108 using a Black Scholesoption pricing model.
No. of securities held after change	Ordinary shares held directly: 566,664Ordinary shares held indirectly: 201,333Options over ordinary shares: 1,120,000

$\pm$ See chapter 19 for defined terms.

Nature of change	Grant of options under Pharmaxis Employee Option Plan
Example: on-market trade, off-market trade, exercise of	as approved at the annual general meeting of the
options, issue of securities under dividend reinvestment plan,	Company on 26 October 2006 and as advised to the
participation in bay-back	ASX on 15 August 2006 and 27 October 2006.

Detail of contract	N/A
Nature of interest
Name of registered holder(if issued securities)
Date of change
No. and class of securities towhich interest related prior tochangeNote: Details are only required for a contract in relationto which the interest has changed
Interest acquired
Interest disposed
Value/ConsiderationNote: If consideration is non-cash, provide details andan estimated valuation.
Interest after change

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

		Name of entity PHARMAXIS LTD
ABN.	75 082 811 630

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Malcolm John McComas
Date of last notice	18 November 2005

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Change in direct interest
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to therelevant interest.
Date of change	26 October 2006
No. of securities held prior to change	Ordinary shares held indirectly: 126,666Options over ordinary shares: 220,000
Class	Unlisted options
Number acquired	$20,000$ options
Number disposed	Nil
Value/ConsiderationNote: II consideration is non-cash, provide details andestimated valuation.	Granted under Pharmaxis Employee Option Plan for nilconsideration. Value of $26,554 using a Black Scholesoption pricing model.
No. of securities held after change	Ordinary shares held indirectly: 126,666Options over ordinary shares: 240,000

$\pm$ See chapter 19 for defined terms.

Nature of change	Grant of options under Pharmaxis Employee Option Plan
Example: on-market trade, off-market trade, exercise of	as approved at the annual general meeting of the
options, issue of securities under dividend reinvestment plan.	Company on 26 October 2006 and as advised to the
participation in bay-back	ASX on 15 August 2006 and 27 October 2006.

Detail of contract	N/A
Nature of interest
Name of registered holder(if issued securities)
Date of change
No. and class of securities towhich interest related prior tochangeNote: Details are only required for a contract in relationto which the interest has changed
Interest acquired
Interest disposed
Value/ConsiderationNote: If consideration is non-cash, provide details andan estimated valuation.
Interest after change

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

		Name of entity PHARMAXIS LTD
ABN.	75 082 811 630

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Charles Peter Hunt Kiefel
Date of last notice	18 November 2005

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Direct
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to therelevant interest.
Date of change	26 October 2006
No. of securities held prior to change	Ordinary shares held directly: 200,000Options over ordinary shares: 220,000
Class	Unlisted options
Number acquired	48,957 options
Number disposed	Nil
Value/ConsiderationNote: II consideration is non-cash, provide details andestimated valuation.	Granted under Pharmaxis Employee Option Plan for nilconsideration. Value of $65,000 using a Black Scholesoption pricing model.
No. of securities held after change	Ordinary shares held indirectly: 200,000Options over ordinary shares: 268,957

$\pm$ See chapter 19 for defined terms.

Nature of change	Grant of options under Pharmaxis Employee Option Plan
Example: on-market trade, off-market trade, exercise of	as approved at the annual general meeting of the
options, issue of securities under dividend reinvestment plan,	Company on 26 October 2006 and as advised to the
participation in bay-back	ASX on 15 August 2006 and 27 October 2006.

Detail of contract	N/A
Nature of interest
Name of registered holder(if issued securities)
Date of change
No. and class of securities towhich interest related prior tochangeNote: Details are only required for a contract in relationto which the interest has changed
Interest acquired
Interest disposed
Value/ConsiderationNote: If consideration is non-cash, provide details andan estimated valuation.
Interest after change

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

		Name of entity PHARMAXIS LTD
ABN	75 082 811 630

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Peter C Farrell
Date of last notice	8 May 2006

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Change in direct interest
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to therelevant interest.
Date of change	26 October 2006
No. of securities held prior to change	Ordinary shares held directly: 101,645Options over ordinary shares: Nil
Class	Unlisted options
Number acquired	$220,000$ options
Number disposed	Nil
Value/ConsiderationNote: If consideration is non-eash, provide details andestimated valuation	Granted under Pharmaxis Employee Option Plan for nilconsideration. Value of $307,814 using a Black Scholesoption pricing model.
No. of securities held after change	Ordinary shares held indirectly: 101,645Options over ordinary shares: 220,000

$\pm$ See chapter 19 for defined terms.

Nature of change	Grant of options under Pharmaxis Employee Option Plan
Example: on-market trade, off-market trade, exercise of	as approved at the annual general meeting of the
options, issue of securities under dividend reinvestment plan,	Company on 26 October 2006 and as advised to the
participation in bay-back	ASX on 15 August 2006 and 27 October 2006.

Detail of contract	N/A
Nature of interest
Name of registered holder(if issued securities)
Date of change
No. and class of securities towhich interest related prior tochangeNote: Details are only required for a contract in relationto which the interest has changed
Interest acquired
Interest disposed
Value/ConsiderationNote: If consideration is non-cash, provide details andan estimated valuation.
Interest after change

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

		Name of entity PHARMAXIS LTD
ABN.	75 082 811 630

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Alan Duncan Robertson
Date of last notice	18 November 2005

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Direct
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to therelevant interest.
Date of change	26 October 2006
No. of securities held prior to change	Options over ordinary shares: 2,230,000
Class	Unlisted options
Number acquired	150,000 options
Number disposed	Nil
Value/ConsiderationNote: If consideration is non-eash, provide details andestimated valuation.	Granted under Pharmaxis Employee Option Plan for nilconsideration. Value of $199,155 using a Black Scholesoption pricing model.
No. of securities held after change	Options over ordinary shares: 2,380,000

$\pm$ See chapter 19 for defined terms.

Nature of change	Grant of options under Pharmaxis Employee Option Plan
Example: on-market trade, off-market trade, exercise of	as approved at the annual general meeting of the
options, issue of securities under dividend reinvestment plan,	Company on 26 October 2006 and as advised to the
participation in bay-back	ASX on 15 August 2006 and 27 October 2006.

Detail of contract	N/A
Nature of interest
Name of registered holder(if issued securities)
Date of change
No. and class of securities towhich interest related prior tochangeNote: Details are only required for a contract in relationto which the interest has changed
Interest acquired
Interest disposed
Value/ConsiderationNote: If consideration is non-cash, provide details andan estimated valuation.
Interest after change

+ See chapter 19 for defined terms.